statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, DOMA, CALT on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, DOMA, CALT on Behalf of Shareholders SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, DOMA, CALT on Behalf of Shareholders...

STOCKHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring August 30, 2024, for shares of Calliditas Therapeutics AB - CALT

STOCKHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring August 30, 2024, for shares of Calliditas Therapeutics AB - CALT STOCKHOLDER...

Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo for the treatment of IgA Nephropathy

Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo for the treatment of IgA Nephropathy Calliditas partner STADA receives European Commission decision for...

Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis

Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis PR Newswire...

Launch of Phase 3 clinical trial with Nefecon in Japan

Launch of Phase 3 clinical trial with Nefecon in Japan Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM, July 4, 2024 STOCKHOLM, July 4, 2024 /PRNewswire/ -- Calliditas...

Calliditas provides setanaxib patent update

Calliditas provides setanaxib patent update Calliditas provides setanaxib patent update PR Newswire STOCKHOLM, June 18, 2024 STOCKHOLM, June 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB...

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) PR Newswire STOCKHOLM, June 17, 2024...

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 18, 2024, for shares of Calliditas Therapeutics AB - CALT

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 18, 2024, for shares of Calliditas Therapeutics AB - CALT STOCKHOLDER...

SHAREHOLDER UPDATE: Halper Sadeh LLC Continues to Investigate OSG, IBTX, CALT, SSB

SHAREHOLDER UPDATE: Halper Sadeh LLC Continues to Investigate OSG, IBTX, CALT, SSB SHAREHOLDER UPDATE: Halper Sadeh LLC Continues to Investigate OSG, IBTX, CALT, SSB PR Newswire NEW YORK, June 3...

Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo for the treatment of IgA nephropathy

Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo for the treatment of IgA nephropathy Calliditas partner STADA receives positive CHMP opinion...

Calliditas Therapeutics AB clinical-stage biopharmaceutical company. It engages in the identification, development, and commercialization of novel treatments in orphan indications. The firm focuses on renal and hepatic diseases with significant unmet medical needs. It offers Nefecon, a proprietary, novel oral formulation of budesonide for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN. The firm product TARPEYO is used to reduce proteinuria in adults with primary immunoglobulin. The company was founded by Mikael Bender and Bengt Åke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.

Volume	3,638.00
52-Wk High	$41.90
52-Wk Low	$15.25

CALT Calliditas Therapeutics AB - ADR

About

Feed

News

Sentiment

Earnings

Fundamentals